Purpose: The association between glycated hemoglobin (HbA1c), medication use/adherence, and mortality stratified by race/ethnicity was examined in a national cohort of veterans with type 2 diabetes.
Methods: A total of 892,223 veterans with diabetes in 2002 were followed through 2006. HbA1c category was the main exposure (i.e., HbA1c <7%, HbA1c 7%-8% [reference], HbA1c 8%-9%, and HbA1c >9%). Covariates included age, sex, marital status, rural/urban residence, geographic region, number of comorbidities, and diabetes medication use/adherence (i.e., adherent, medication possession ratio ≥80%; nonadherent; and nonusers). HbA1c and medication use/adherence varied over time, and Cox regression models accounting for time-varying variables were used.
Results: In nonmedication users, HbA1c greater than 9% predicted higher mortality risk relative to HbA1c of 7%-8% in non-Hispanic whites (hazard ratio [HR], 1.55; 95% confidence interval [95% CI], 1.43-1.69), non-Hispanic blacks (NHB) (HR, 1.58; 95% CI, 1.34-1.87), and Hispanics (HR, 2.22; 95% CI, 1.75-2.82). In contrast, in nonadherent medication users, HbA1c less than 7% predicted higher mortality risk in NHB (HR, 1.12; 95% CI, 1.05-1.20), whereas HbA1c greater than 9% only predicted mortality in non-Hispanic whites (HR, 1.11; 95% CI, 1.06-1.16). In adherent medication users, HbA1c less than 7% predicted higher mortality in NHB (HR, 1.18; 95% CI, 1.07-1.31), whereas HbA1c greater than 9.0% predicted higher mortality risk across all race/ethnic groups.
Conclusion: We found evidence for racial/ethnic differences in the association between glycemic control and mortality, which varied by medication use/adherence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annepidem.2012.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous immunoglobulin therapy: usage patterns and response to treatment in Qatar over ten years.
Front Immunol
December 2024
Allergy and Immunology Division, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Background: IVIg is a blood-derived antibody product initially designed as a replacement therapy in inborn errors of immunity (IEIs). However, over the last 50 years, IVIg has been used to treat a growing range of autoimmune, autoinflammatory, and secondary immunodeficiency disorders. The US FDA has licensed IVIg for use in the treatment of nine clinical indications; although, IVIg global usage extends to off-label indications with variable treatment responses.
View Article and Find Full Text PDFIndividual & joint associations of sexual stigma and mental distress with PrEP uptake, adherence and persistence among US gay and bisexual men.
Soc Sci Med
December 2024
Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins University, Baltimore, MD, United States.
Article Synopsis
- - The study investigates how sexual stigma, mental health issues, and economic disparities affect the use and consistency of PrEP among gay men and other men who have sex with men (MSM), aiming to understand these complex interactions.
- - Analyzing data from the American Men's Internet Survey, researchers identified four different classes of sexual stigma and found that when combined with mental distress, these factors significantly lowered the likelihood of PrEP use and adherence.
- - The findings suggest a need for targeted interventions that consider these psychosocial factors to improve PrEP uptake and adherence among MSM, which can lead to better health outcomes.
Comparing the impact of targeting limited driving pressure to low tidal volume ventilation on mortality in mechanically ventilated adults with COVID-19 ARDS: an exploratory target trial emulation.
BMJ Open Respir Res
October 2024
Pharmacy and Health Systems Sciences, Northeastern University - Boston Campus, Boston, Massachusetts, USA.
Article Synopsis
- There may be a connection between driving pressure (∆P) during invasive mechanical ventilation (IMV) and patient outcomes, particularly in those with acute respiratory distress syndrome (ARDS) related to COVID-19 (C-ARDS).
- This study aimed to see if maintaining a daily ∆P of less than 15 cm HO, in conjunction with low tidal volume ventilation (LTVV), improves 28-day mortality compared to using LTVV alone.
- Results showed that while 28-day survival rates varied among the groups, limiting ∆P did not appear to provide significant additional survival benefits compared to LTVV alone, suggesting a need for further research in this area.
Occupational post-exposure prophylaxis among healthcare workers: a scoping review of factors affecting optimal utilization.
J Int AIDS Soc
August 2024
Andrew Forsyth Consulting, Berkeley, California, USA.
Introduction: Post-exposure prophylaxis (PEP) is an efficacious prevention method when initiated promptly after an HIV exposure. Yet, PEP has been underutilized, even among healthcare workers (HCWs) with occupational exposure in sites with PEP policies and procedures and access to PEP medications. It is important to understand the dynamics of uneven PEP use in what appears to be an optimal context to better protect the health and wellbeing of HCWs.
View Article and Find Full Text PDFTelemedicine for Patients With Systemic Lupus Erythematosus in a Publicly Funded Hospital System: Retrospective Study.
Interact J Med Res
November 2024
Department of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, United States.
Article Synopsis
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with high no-show rates for clinic visits, especially among underserved patients.
- A study compared no-show rates for telemedicine visits during the COVID-19 pandemic to in-person visits from 2018 to 2020, revealing that telemedicine had a significantly lower no-show rate of 5.5% compared to 16.2% for in-person visits.
- Results indicated that telemedicine reduced the likelihood of no-shows without affecting adherence to necessary laboratory tests, suggesting it may be an effective alternative for patient appointments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!